US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acrivon Therapeutics, Inc.

1.35

+0.10008.00%

Post-market: 1.34-0.0099-0.73%19:59 EDT

Volume:688.59K

Turnover:914.65K

Market Cap:42.33M

PE:-0.61

High:1.37

Open:1.26

Low:1.24

Close:1.25

Loading ...

Overview Company News Filings

Acrivon Therapeutics, Inc Q4 Income From Operations USD -24.954 Million

Press Release: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics Inc - Q4 Shr Loss $0.60

THOMSON REUTERS

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings

Acrivon Therapeutics Price Target Maintained With a $17.00/Share by Citizens Capital Markets

Calendar of U.S. Earnings Expected in the Week Ahead

Calendar of U.S. Earnings Expected in the Week Ahead

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical Acr-368 and Acr-2316 Program Updates

THOMSON REUTERS

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics announces FDA granted BDD for ACR-368

Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status

Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation

MT Newswires Live

Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification

Acrivon Therapeutics Announces FDA Has Granted Breakthrough Device Designation for Acr-368 Oncosignature Assay for Endometrial Cancer

THOMSON REUTERS

Acrivon Therapeutics Initiated at Overweight by Cantor Fitzgerald

Acrivon Therapeutics, Inc. (ACRV) Initiated with a Buy at Cantor Fitzgerald

Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACRV/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACRV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","market":"US","secType":"STK","nameCN":"Acrivon Therapeutics, Inc.","latestPrice":1.35,"timestamp":1749240000000,"preClose":1.25,"halted":0,"volume":688590,"hourTrading":{"tag":"盘后","latestPrice":1.3401,"preClose":1.35,"latestTime":"19:59 EDT","volume":3276,"amount":4418.4327,"timestamp":1749254394147},"delay":0,"floatShares":13572312,"shares":31355361,"eps":-2.219617,"marketStatus":"Market Closed","change":0.1,"latestTime":"06-06 16:00:00 EDT","open":1.26,"high":1.37,"low":1.24,"amount":914651.8246530001,"amplitude":0.104,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.219617,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1668488400000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.2403,"preClose":1.25,"latestTime":"09:05 EDT","volume":1943,"amount":2414.3304141,"timestamp":1749215108757},"postHourTrading":{"tag":"盘后","latestPrice":1.3401,"preClose":1.35,"latestTime":"19:59 EDT","volume":3276,"amount":4418.4327,"timestamp":1749254394147},"volumeRatio":1.0005126140959049},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","floatShares":13572312,"roa":"-39.24%","roe":"-62.41%","lyrEps":-2.38389,"volumeRatio":1.0005126140959049,"shares":31355361,"dividePrice":0,"high":1.37,"amplitude":0.104,"preClose":1.25,"low":1.24,"week52Low":1.05,"pbRate":"0.26","week52High":10.16,"institutionHeld":0,"latestPrice":1.35,"eps":-2.219617,"divideRate":0,"volume":688590,"delay":0,"ttmEps":-2.219617,"open":1.26,"prevYearClose":6.02,"prevWeekClose":1.05,"prevMonthClose":1.05,"prevQuarterClose":2.03,"fiveDayClose":1.05,"twentyDayClose":1.18,"sixtyDayClose":5.33},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACRV\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522582595","title":"Acrivon Therapeutics, Inc Q4 Income From Operations USD -24.954 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522582595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522582595?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:01","pubTimestamp":1743112904,"startTime":"0","endTime":"0","summary":"Mar 27 (Reuters) - Acrivon Therapeutics, Inc Q4 operating expenses USD 24.954 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-MAR-202521:40:00.063 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nRSD5kjW68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2522530052","title":"Press Release: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522530052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522530052?lang=en_us&edition=fundamental","pubTime":"2025-03-28 05:44","pubTimestamp":1743111840,"startTime":"0","endTime":"0","summary":"Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects. R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heavily pretreated aggressive tumors, and who had all progressed on prior anti-PD-1 and chemotherapy, with 35% confirmed overall response rate , which is >2-fold higher than last prior line of therapy (15%). In the BM+ patients who had relapsed after prior anti-PD-1 and chemotherapy, the cORR was 50% with the median duration of response  not yet reached , while in BM+ patients who were refractory to their last prior line of therapy, the cORR was 33% and mDOR was 3.4 months","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACRV","BK4139"],"gpt_icon":0},{"id":"2522532879","title":"Acrivon Therapeutics Inc - Q4 Shr Loss $0.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532879?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:50","pubTimestamp":1743108626,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1I9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2522387694","title":"Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387694","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387694?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:28","pubTimestamp":1743006506,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44498176/crude-oil-gains-over-1-cintas-shares-jump-after-q3-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICG","WOR","VVPR","ACON","CTAS","ACRV","OSRH"],"gpt_icon":0},{"id":"2522805787","title":"Acrivon Therapeutics Price Target Maintained With a $17.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805787","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805787?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:10","pubTimestamp":1742994600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:10 ET (13:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACRV"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","LPTX","OBIO","SLRN","MDAI","GOVX","CNXC","IOBT","BCAB","PAYX","THRD","WOOF","ALUR","EDAP","WGO","ZURA","ANTX","CRMD","CALC","CLSD","PDSB","PAYS","RVPH","ACRV","SDST","DLTR","NUTX","TEN","CTAS","WBA","ABL","BEEM","KOD","IKT","SURG","XFOR","CHWY","DERM","SKYX","FBIO","MREO","MKC","IVA","KBH","UNCY","CDLR","GRDN","AFMD","SCS","MLKN"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JKS","BBNX","ASO","FLUX","NKTX","MREO","FBRX","TELA","DERM","MBRX","LPTX","IFRX","DRI","COYA","NKE","SOWG","SBS","OUST","KLC","RUM","BCAB","WOR","SKYE","BLRX","RLMD","LEN","SLS","CURV","JEF","LVTX","CELC","BRAG","PL","CBUS","PAYX","ACRV","CDLR","TH","TITN","THRD","MLKN","MNSO","ALUR","MGNX","BRNS","CMC","GDEV","SPRY"],"gpt_icon":1},{"id":"2520713188","title":"Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical Acr-368 and Acr-2316 Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520713188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520713188?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA1ZHGFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2520185764","title":"Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520185764","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520185764?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385600,"startTime":"0","endTime":"0","summary":"Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET. To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner yielding terabytes of high resolution proprietary quantitative data for pathway-based drug design, indication finding, and response prediction. These distinctive capabilities enable AP3’s direct application for streamlined rati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-host-corporate-r-120000156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","ACR","BK4218","LENZ","BK4110","ACRV","BK4588","HST","GCIG","BK4139","BK4585"],"gpt_icon":0},{"id":"2509275558","title":"Acrivon Therapeutics announces FDA granted BDD for ACR-368","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275558","media":"TipRanks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275558?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:16","pubTimestamp":1738847797,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics  announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment. The designation reflects the FDA’s determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient selection.Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  Your Smart Portfolio. Acrivo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-fda-granted-131637686.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-fda-granted-131637686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","BDD","ACR","ACRV","BK4139","LENZ"],"gpt_icon":0},{"id":"2509562262","title":"Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2509562262","media":"Insider Monkey","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509562262?lang=en_us&edition=fundamental","pubTime":"2025-02-06 04:45","pubTimestamp":1738788331,"startTime":"0","endTime":"0","summary":"We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to take a look at where Acrivon Therapeutics, Inc.  stands against other AI news and ratings investors are keeping their eye on.Josh Wolfe, co-founder of Lux Capital, discussed the current AI space and the increasing importance of both capital and human talent in the field as he joined Caroline Hyde and Mike Shepard on “Bloomberg Technology.” He highlighted how investments in large foundation models, previously seen as groundbreaking, are being overshadowed by more cost-effective open-source models and the rise of novel AI applications, especially in physical intelligence, robotics, and biology.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-acrv-ai-powered-204531073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4139","ACRV","SQQQ","QLD","TQQQ","USAW.SI",".IXIC","TSYW.SI","USJW.SI","NQmain","QID","PSQ","NVIW.SI"],"gpt_icon":1},{"id":"2509233509","title":"Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2509233509","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509233509?lang=en_us&edition=fundamental","pubTime":"2025-02-05 23:43","pubTimestamp":1738770196,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics  said Wednesday the US Food and Drug Administration has granted its ACR-368 OncoSignature Assay Breakthrough Device designation.The assay is designed to identify endometrial cancer patients who are likely to respond to the company's ACR-368 treatment, the company said. The designation accelerates the product's development, assessment, and review for approvals.Shares of Acrivon Therapeutics were up nearly 21% in recent Wednesay trading.Price: 7.15, Change: +1.24, Percent Change: +20.98","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4110","BK4139","ACR","ACRV"],"gpt_icon":0},{"id":"2509944285","title":"Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification","url":"https://stock-news.laohu8.com/highlight/detail?id=2509944285","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509944285?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:20","pubTimestamp":1738761600,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment.The precision medicine company said the new designation reflects the FDA's determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.The company said it sponsored a blind, third-party market research study, which showed strong interest in the emerging clinical profile of ACR-368.The Breakthrough Devices Program is intended to provide patients and health-care providers with timely access to medical devices by speeding up development, assessment and review for premarket approval, 510 clearance, and marketing authorization.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","ACRV"],"gpt_icon":0},{"id":"2509833162","title":"Acrivon Therapeutics Announces FDA Has Granted Breakthrough Device Designation for Acr-368 Oncosignature Assay for Endometrial Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509833162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509833162?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA285XRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2507096107","title":"Acrivon Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2507096107","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507096107?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:32","pubTimestamp":1738337520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 31, 2025 10:32 ET (15:32 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","LENZ"],"gpt_icon":0},{"id":"2507987968","title":"Acrivon Therapeutics, Inc. (ACRV) Initiated with a Buy at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2507987968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507987968?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:36","pubTimestamp":1738330603,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics, Inc. (ACRV – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Li Watsek today. The comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acrivon-therapeutics-inc-acrv-initiated-with-a-buy-at-cantor-fitzgerald?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acrivon-therapeutics-inc-acrv-initiated-with-a-buy-at-cantor-fitzgerald?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2507695773","title":"Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2507695773","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507695773?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:12","pubTimestamp":1738329132,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics (ACRV) has an average rating of buy and mean price target of $21.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ACRV"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACRV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"ACRV","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.51},{"market":"US","date":"2025-03-27","symbol":"ACRV","fiscalQuarterEnding":"2024/12","expectedEps":-0.69,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACRV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACRV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1747454400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACRV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACRV","date":"2025-06-06","current":-0.46799,"percent":0.968153,"low":-18.228389,"twenty":-7.860449,"median":-3.572307,"eighty":-2.185046,"high":-0.393112,"avg":-5.076058,"sd":4.080584,"marketCap":39194201},"quantilePoints":[{"date":"2022-11-11","current":-11.86111,"twenty":-16.13111,"median":-16.13111,"eighty":-13.56911,"marketCap":235122787},{"date":"2022-11-18","current":-16.605358,"twenty":-17.148347,"median":-16.336664,"eighty":-13.56911,"marketCap":329168006},{"date":"2022-11-25","current":-13.1538,"twenty":-16.59273,"median":-14.65824,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-02","current":-13.311646,"twenty":-16.459997,"median":-13.18537,"eighty":-13.1538,"marketCap":263876760},{"date":"2022-12-09","current":-13.1538,"twenty":-16.13111,"median":-13.18537,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-16","current":-9.42062,"twenty":-15.609309,"median":-13.164324,"eighty":-13.1538,"marketCap":250409495},{"date":"2022-12-23","current":-9.15348,"twenty":-13.492642,"median":-13.1538,"eighty":-9.908718,"marketCap":243308642},{"date":"2022-12-30","current":-9.051338,"twenty":-13.374784,"median":-13.1538,"eighty":-9.15348,"marketCap":240593610},{"date":"2023-01-06","current":-9.114194,"twenty":-13.324274,"median":-13.1538,"eighty":-9.10948,"marketCap":242264399},{"date":"2023-01-13","current":-9.758474,"twenty":-13.286391,"median":-13.1538,"eighty":-9.096909,"marketCap":259389986},{"date":"2023-01-20","current":-11.102032,"twenty":-13.261136,"median":-11.86111,"eighty":-9.107908,"marketCap":295103100},{"date":"2023-01-27","current":-11.416314,"twenty":-13.210625,"median":-11.432028,"eighty":-9.118908,"marketCap":303457044},{"date":"2023-02-03","current":-14.967707,"twenty":-13.261136,"median":-11.549884,"eighty":-9.140908,"marketCap":397856621},{"date":"2023-02-10","current":-17.254113,"twenty":-13.707494,"median":-12.294777,"eighty":-9.280764,"marketCap":458631569},{"date":"2023-02-17","current":-16.963401,"twenty":-16.209458,"median":-13.1538,"eighty":-9.39862,"marketCap":450904170},{"date":"2023-02-24","current":-12.044879,"twenty":-16.13111,"median":-12.885585,"eighty":-9.423763,"marketCap":320164934},{"date":"2023-03-03","current":-16.499835,"twenty":-16.177918,"median":-13.1538,"eighty":-9.434763,"marketCap":438582102},{"date":"2023-03-10","current":-15.745556,"twenty":-16.430693,"median":-13.1538,"eighty":-9.447334,"marketCap":418532634},{"date":"2023-03-17","current":-15.714128,"twenty":-16.525265,"median":-13.1538,"eighty":-9.527476,"marketCap":417697240},{"date":"2023-03-24","current":-10.229897,"twenty":-16.430693,"median":-13.1538,"eighty":-9.461476,"marketCap":271920903},{"date":"2023-03-31","current":-8.928026,"twenty":-16.282979,"median":-13.1538,"eighty":-9.434763,"marketCap":278259784},{"date":"2023-04-06","current":-7.274688,"twenty":-16.215409,"median":-13.019693,"eighty":-9.37662,"marketCap":226730194},{"date":"2023-04-14","current":-6.723819,"twenty":-16.19352,"median":-12.044879,"eighty":-9.115765,"marketCap":209561261},{"date":"2023-04-21","current":-8.060143,"twenty":-16.13111,"median":-11.86111,"eighty":-9.056052,"marketCap":251210465},{"date":"2023-04-28","current":-8.650938,"twenty":-16.126284,"median":-11.549884,"eighty":-9.035624,"marketCap":269623798},{"date":"2023-05-05","current":-7.956584,"twenty":-16.088124,"median":-11.377028,"eighty":-8.91982,"marketCap":247982856},{"date":"2023-05-12","current":-8.118522,"twenty":-16.003268,"median":-11.21203,"eighty":-8.835959,"marketCap":297974095},{"date":"2023-05-19","current":-7.88554,"twenty":-15.962411,"median":-10.807392,"eighty":-8.673871,"marketCap":289422962},{"date":"2023-05-26","current":-7.467367,"twenty":-15.908983,"median":-10.229897,"eighty":-8.438641,"marketCap":274074775},{"date":"2023-06-02","current":-7.419576,"twenty":-15.745556,"median":-9.829187,"eighty":-8.257075,"marketCap":272320696},{"date":"2023-06-09","current":-7.353863,"twenty":-15.714128,"median":-9.671273,"eighty":-8.064756,"marketCap":269908838},{"date":"2023-06-16","current":-7.138803,"twenty":-14.967707,"median":-9.475619,"eighty":-7.88554,"marketCap":262015484},{"date":"2023-06-23","current":-7.694375,"twenty":-14.936279,"median":-9.444191,"eighty":-7.691985,"marketCap":282406648},{"date":"2023-06-30","current":-7.957226,"twenty":-14.607853,"median":-9.4246,"eighty":-7.737387,"marketCap":292054080},{"date":"2023-07-07","current":-6.962573,"twenty":-14.230714,"median":-9.36562,"eighty":-7.687206,"marketCap":255547320},{"date":"2023-07-14","current":-7.312046,"twenty":-13.800187,"median":-9.122051,"eighty":-7.479315,"marketCap":268374019},{"date":"2023-07-21","current":-7.795931,"twenty":-13.463178,"median":-9.09848,"eighty":-7.467367,"marketCap":286134065},{"date":"2023-07-28","current":-7.335941,"twenty":-13.349529,"median":-9.063123,"eighty":-7.467367,"marketCap":269251058},{"date":"2023-08-04","current":-7.049195,"twenty":-13.305332,"median":-9.04741,"eighty":-7.451835,"marketCap":258726587},{"date":"2023-08-11","current":-6.929717,"twenty":-13.273763,"median":-9.035624,"eighty":-7.414797,"marketCap":254341391},{"date":"2023-08-18","current":-5.439761,"twenty":-13.23588,"median":-8.933664,"eighty":-7.374175,"marketCap":243684992},{"date":"2023-08-25","current":-5.824092,"twenty":-13.18537,"median":-8.917768,"eighty":-7.335941,"marketCap":260901867},{"date":"2023-09-01","current":-5.774819,"twenty":-13.181161,"median":-8.846512,"eighty":-7.295319,"marketCap":258694575},{"date":"2023-09-08","current":-5.764965,"twenty":-13.164324,"median":-8.810263,"eighty":-7.252307,"marketCap":258253117},{"date":"2023-09-15","current":-5.415125,"twenty":-13.164324,"median":-8.657972,"eighty":-7.138803,"marketCap":242581346},{"date":"2023-09-22","current":-4.666172,"twenty":-13.15801,"median":-8.650938,"eighty":-7.070701,"marketCap":209030514},{"date":"2023-09-28","current":-4.848483,"twenty":-13.1538,"median":-8.470778,"eighty":-7.024104,"marketCap":217197493},{"date":"2023-10-06","current":-3.606798,"twenty":-13.1538,"median":-8.337045,"eighty":-6.962573,"marketCap":161573745},{"date":"2023-10-13","current":-3.074648,"twenty":-13.1538,"median":-8.233741,"eighty":-6.723819,"marketCap":137734995},{"date":"2023-10-20","current":-2.670607,"twenty":-13.1538,"median":-8.118522,"eighty":-6.217422,"marketCap":119635204},{"date":"2023-10-27","current":-2.498151,"twenty":-13.1538,"median":-8.106574,"eighty":-6.135872,"marketCap":111909684},{"date":"2023-11-03","current":-2.650898,"twenty":-13.1538,"median":-8.060143,"eighty":-5.913769,"marketCap":118752288},{"date":"2023-11-10","current":-2.023663,"twenty":-13.1538,"median":-7.990082,"eighty":-5.83986,"marketCap":101314684},{"date":"2023-11-17","current":-1.968296,"twenty":-13.1538,"median":-7.956584,"eighty":-5.774819,"marketCap":98542723},{"date":"2023-11-24","current":-1.70231,"twenty":-13.1538,"median":-7.867618,"eighty":-5.710764,"marketCap":85226138},{"date":"2023-12-01","current":-1.795405,"twenty":-12.885585,"median":-7.837749,"eighty":-5.538308,"marketCap":89886943},{"date":"2023-12-08","current":-2.38944,"twenty":-12.728444,"median":-7.795931,"eighty":-5.434834,"marketCap":119627314},{"date":"2023-12-15","current":-2.220982,"twenty":-12.181592,"median":-7.694375,"eighty":-5.139195,"marketCap":111193478},{"date":"2023-12-22","current":-2.158919,"twenty":-11.988308,"median":-7.676453,"eighty":-4.765704,"marketCap":108086275},{"date":"2023-12-29","current":-2.207683,"twenty":-11.903452,"median":-7.658532,"eighty":-4.607044,"marketCap":110527648},{"date":"2024-01-05","current":-2.061391,"twenty":-11.878047,"median":-7.57191,"eighty":-4.424734,"marketCap":103203527},{"date":"2024-01-12","current":-2.136753,"twenty":-11.86111,"median":-7.467367,"eighty":-3.380635,"marketCap":106976559},{"date":"2024-01-19","current":-1.928398,"twenty":-11.771191,"median":-7.467367,"eighty":-3.021433,"marketCap":96545235},{"date":"2024-01-26","current":-1.795405,"twenty":-11.601741,"median":-7.461393,"eighty":-2.812514,"marketCap":89886943},{"date":"2024-02-02","current":-1.711176,"twenty":-11.509027,"median":-7.449445,"eighty":-2.678491,"marketCap":85670025},{"date":"2024-02-09","current":-1.569317,"twenty":-11.435171,"median":-7.416589,"eighty":-2.525448,"marketCap":78567846},{"date":"2024-02-16","current":-1.773239,"twenty":-11.384886,"median":-7.389706,"eighty":-2.417812,"marketCap":88777228},{"date":"2024-02-23","current":-1.693444,"twenty":-11.315743,"median":-7.371785,"eighty":-2.305211,"marketCap":84782252},{"date":"2024-03-01","current":-2.154486,"twenty":-11.224602,"median":-7.341915,"eighty":-2.222755,"marketCap":107864332},{"date":"2024-03-08","current":-2.274179,"twenty":-11.19003,"median":-7.329968,"eighty":-2.220982,"marketCap":113856794},{"date":"2024-03-15","current":-2.247581,"twenty":-11.059604,"median":-7.297111,"eighty":-2.213003,"marketCap":112525136},{"date":"2024-03-22","current":-2.806151,"twenty":-10.856891,"median":-7.272415,"eighty":-2.217436,"marketCap":140489963},{"date":"2024-03-28","current":-2.376071,"twenty":-10.724892,"median":-7.222437,"eighty":-2.220982,"marketCap":143486194},{"date":"2024-04-05","current":-2.507803,"twenty":-10.284897,"median":-7.147764,"eighty":-2.220982,"marketCap":151441202},{"date":"2024-04-12","current":-3.482435,"twenty":-10.229897,"median":-7.085038,"eighty":-2.220982,"marketCap":210297274},{"date":"2024-04-19","current":-5.388706,"twenty":-10.049185,"median":-7.03426,"eighty":-2.229848,"marketCap":325413151},{"date":"2024-04-26","current":-4.330392,"twenty":-9.829187,"median":-6.98405,"eighty":-2.238715,"marketCap":261503737},{"date":"2024-05-03","current":-4.325468,"twenty":-9.758474,"median":-6.941664,"eighty":-2.247581,"marketCap":261206357},{"date":"2024-05-10","current":-4.161857,"twenty":-9.701929,"median":-6.723819,"eighty":-2.252014,"marketCap":251326211},{"date":"2024-05-17","current":-4.122189,"twenty":-9.640618,"median":-6.484687,"eighty":-2.274179,"marketCap":264306537},{"date":"2024-05-24","current":-3.905485,"twenty":-9.530619,"median":-6.182256,"eighty":-2.300778,"marketCap":250411918},{"date":"2024-05-31","current":-3.717675,"twenty":-9.486619,"median":-5.962057,"eighty":-2.304324,"marketCap":238369915},{"date":"2024-06-07","current":-3.49134,"twenty":-9.456762,"median":-5.903338,"eighty":-2.319397,"marketCap":223857757},{"date":"2024-06-14","current":-3.49134,"twenty":-9.445762,"median":-5.863511,"eighty":-2.33713,"marketCap":223857757},{"date":"2024-06-21","current":-3.183139,"twenty":-9.434763,"median":-5.824092,"eighty":-2.361913,"marketCap":204096520},{"date":"2024-06-28","current":-2.793072,"twenty":-9.426151,"median":-5.774819,"eighty":-2.384092,"marketCap":179086205},{"date":"2024-07-05","current":-3.404659,"twenty":-9.423008,"median":-5.767428,"eighty":-2.38944,"marketCap":218299909},{"date":"2024-07-12","current":-3.587653,"twenty":-9.39862,"median":-5.666418,"eighty":-2.403626,"marketCap":230033143},{"date":"2024-07-19","current":-3.529865,"twenty":-9.280764,"median":-5.543235,"eighty":-2.426576,"marketCap":226327911},{"date":"2024-07-26","current":-4.266659,"twenty":-9.140908,"median":-5.474253,"eighty":-2.441598,"marketCap":273569617},{"date":"2024-08-02","current":-3.63581,"twenty":-9.122051,"median":-5.42498,"eighty":-2.474845,"marketCap":233120836},{"date":"2024-08-09","current":-3.703229,"twenty":-9.118908,"median":-5.388706,"eighty":-2.497195,"marketCap":237443607},{"date":"2024-08-16","current":-3.411328,"twenty":-9.107908,"median":-5.155584,"eighty":-2.500122,"marketCap":235388438},{"date":"2024-08-23","current":-4.201319,"twenty":-9.095337,"median":-5.020597,"eighty":-2.503539,"marketCap":289899445},{"date":"2024-08-30","current":-4.259671,"twenty":-9.084337,"median":-4.902952,"eighty":-2.504417,"marketCap":293925826},{"date":"2024-09-06","current":-3.62678,"twenty":-9.070195,"median":-4.859549,"eighty":-2.505321,"marketCap":250255077},{"date":"2024-09-13","current":-3.999333,"twenty":-9.051338,"median":-4.841316,"eighty":-2.507803,"marketCap":275961972},{"date":"2024-09-20","current":-3.352976,"twenty":-9.049767,"median":-4.688345,"eighty":-2.511616,"marketCap":231362057},{"date":"2024-09-27","current":-3.21383,"twenty":-9.04191,"median":-4.607044,"eighty":-2.532949,"marketCap":221760687},{"date":"2024-10-04","current":-3.146501,"twenty":-9.035624,"median":-4.498696,"eighty":-2.562206,"marketCap":217114862},{"date":"2024-10-11","current":-3.272182,"twenty":-9.016796,"median":-4.434588,"eighty":-2.595712,"marketCap":225787068},{"date":"2024-10-18","current":-3.703086,"twenty":-8.941048,"median":-4.32793,"eighty":-2.65484,"marketCap":255520344},{"date":"2024-10-25","current":-3.572917,"twenty":-8.937048,"median":-4.281106,"eighty":-2.672533,"marketCap":246538417},{"date":"2024-11-01","current":-3.59536,"twenty":-8.928026,"median":-4.264137,"eighty":-2.682254,"marketCap":248087025},{"date":"2024-11-08","current":-3.846721,"twenty":-8.925974,"median":-4.246205,"eighty":-2.692288,"marketCap":265431436},{"date":"2024-11-15","current":-2.815239,"twenty":-8.917768,"median":-4.204595,"eighty":-2.703682,"marketCap":216708620},{"date":"2024-11-22","current":-2.649398,"twenty":-8.907034,"median":-4.16553,"eighty":-2.65484,"marketCap":203942738},{"date":"2024-11-29","current":-3.066021,"twenty":-8.864099,"median":-4.160922,"eighty":-2.670607,"marketCap":236013123},{"date":"2024-12-06","current":-2.596815,"twenty":-8.828924,"median":-4.126009,"eighty":-2.650898,"marketCap":199895020},{"date":"2024-12-13","current":-2.855687,"twenty":-8.814854,"median":-4.120525,"eighty":-2.670607,"marketCap":219822249},{"date":"2024-12-20","current":-2.714117,"twenty":-8.805671,"median":-4.068333,"eighty":-2.680238,"marketCap":208924546},{"date":"2024-12-27","current":-2.394571,"twenty":-8.751109,"median":-4.0331,"eighty":-2.645353,"marketCap":184326872},{"date":"2025-01-03","current":-2.677713,"twenty":-8.689771,"median":-4.012605,"eighty":-2.604905,"marketCap":206122279},{"date":"2025-01-10","current":-2.212551,"twenty":-8.655158,"median":-3.960865,"eighty":-2.587876,"marketCap":170315539},{"date":"2025-01-17","current":-2.337942,"twenty":-8.650938,"median":-3.900584,"eighty":-2.551877,"marketCap":179967790},{"date":"2025-01-24","current":-2.204461,"twenty":-8.625618,"median":-3.852513,"eighty":-2.521343,"marketCap":169692813},{"date":"2025-01-31","current":-2.455244,"twenty":-8.502914,"median":-3.835171,"eighty":-2.504323,"marketCap":188997316},{"date":"2025-02-07","current":-2.43502,"twenty":-8.401182,"median":-3.809173,"eighty":-2.50322,"marketCap":187440501},{"date":"2025-02-14","current":-2.192327,"twenty":-8.329184,"median":-3.763471,"eighty":-2.461772,"marketCap":168758724},{"date":"2025-02-21","current":-2.240865,"twenty":-8.297738,"median":-3.75246,"eighty":-2.43502,"marketCap":172495079},{"date":"2025-02-28","current":-2.147833,"twenty":-8.257075,"median":-3.717675,"eighty":-2.390526,"marketCap":165333731},{"date":"2025-03-07","current":-2.240865,"twenty":-8.210407,"median":-3.714869,"eighty":-2.366257,"marketCap":172495079},{"date":"2025-03-14","current":-2.200416,"twenty":-8.154365,"median":-3.703229,"eighty":-2.322944,"marketCap":169381450},{"date":"2025-03-21","current":-2.168057,"twenty":-8.118522,"median":-3.698597,"eighty":-2.300778,"marketCap":166890546},{"date":"2025-03-28","current":-0.871783,"twenty":-8.106574,"median":-3.680643,"eighty":-2.269179,"marketCap":70227315},{"date":"2025-04-04","current":-0.587675,"twenty":-8.064756,"median":-3.655072,"eighty":-2.252014,"marketCap":47340734},{"date":"2025-04-11","current":-0.630486,"twenty":-8.060143,"median":-3.640625,"eighty":-2.24491,"marketCap":50789397},{"date":"2025-04-17","current":-0.704431,"twenty":-8.039938,"median":-3.63581,"eighty":-2.240865,"marketCap":56746178},{"date":"2025-04-25","current":-0.638341,"twenty":-8.020549,"median":-3.631295,"eighty":-2.235426,"marketCap":51422173},{"date":"2025-05-02","current":-0.548817,"twenty":-7.973953,"median":-3.617803,"eighty":-2.223945,"marketCap":44210527},{"date":"2025-05-09","current":-0.451509,"twenty":-7.958421,"median":-3.612522,"eighty":-2.214841,"marketCap":36371781},{"date":"2025-05-16","current":-0.430551,"twenty":-7.956712,"median":-3.606138,"eighty":-2.211394,"marketCap":36058665},{"date":"2025-05-23","current":-0.430551,"twenty":-7.899749,"median":-3.596322,"eighty":-2.204461,"marketCap":36058665},{"date":"2025-05-30","current":-0.411832,"twenty":-7.874787,"median":-3.589262,"eighty":-2.194384,"marketCap":34490897},{"date":"2025-06-06","current":-0.46799,"twenty":-7.860449,"median":-3.572307,"eighty":-2.185046,"marketCap":39194201}],"updateTime":1749417650740}}}